File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels
  • Basic View
  • Metadata View
  • XML View
TitleRisk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels
 
AuthorsYuen, MF2
Tanaka, Y1
Shinkai, N1
Poon, RT2
But, DYK2
Fong, DYT2
Fung, J2
Wong, DKH2
Yuen, JCH2
Mizokami, M1
Lai, CL2
 
Issue Date2008
 
PublisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
 
CitationGut, 2008, v. 57 n. 1, p. 98-102 [How to Cite?]
DOI: http://dx.doi.org/10.1136/gut.2007.119859
 
AbstractBackground/aim: To examine the risks for hepatocellular carcinoma (HCC) with respect to hepatitis B virus (HBV) genotypes, specific viral mutations (MT), serum HBV DNA levels, and cirrhosis. Methods: HBV genotypes, 1653/1753/core promoter (CP)/precore MT and HBV DNA levels were determined in 248 HBV patients with HCC and 248 HBV controls. Results: Genotype C, CP-MT, T1653, HBV DNA levels ≥4 log 10 copies/ml and cirrhosis had a higher risk for HCC compared to patients with genotype B (p = 0.001, OR 1.9), CP wild-type (WT) (p<0.001, OR 4.1), C1653 (p = 0.028, OR 2.4), HBV DNA <4 log 10 copies/ml (p = 0.003, OR 2.1) and without cirrhosis (p<0.001, OR 4.0) respectively. Multivariate analysis showed that CP-MT, T1653, HBV DNA ≥4 log 10 copies/ml and cirrhosis were independent factors for HCC (all p<0.05). A receiver operating characteristics curve showed no cut-off HBV DNA level associated with minimal chance of HCC. Patients with CP-MT and cirrhosis had a 22.2-fold increased risk of HCC compared to patients with CP-WT and without cirrhosis. Patients with CP-MT and HBV DNA levels ≥4 log 10 copies/ml had a 7.2-fold increased risk of HCC compared to patients with CP-WT and HBV DNA levels <4 log 10 copies/ml. Patients with CP-MT and T1653 had a 9.9-fold increased risk of HCC compared to patients with wild-type for both regions. Conclusions: CP-MT, T1653, HBV DNA levels ≥4 log 10 copies/ml and cirrhosis are independent factors for development of HCC. The risks increased substantially in patients having these factors in combination.
 
ISSN0017-5749
2013 Impact Factor: 13.319
 
DOIhttp://dx.doi.org/10.1136/gut.2007.119859
 
ISI Accession Number IDWOS:000251778400021
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorYuen, MF
 
dc.contributor.authorTanaka, Y
 
dc.contributor.authorShinkai, N
 
dc.contributor.authorPoon, RT
 
dc.contributor.authorBut, DYK
 
dc.contributor.authorFong, DYT
 
dc.contributor.authorFung, J
 
dc.contributor.authorWong, DKH
 
dc.contributor.authorYuen, JCH
 
dc.contributor.authorMizokami, M
 
dc.contributor.authorLai, CL
 
dc.date.accessioned2010-04-12T01:39:15Z
 
dc.date.available2010-04-12T01:39:15Z
 
dc.date.issued2008
 
dc.description.abstractBackground/aim: To examine the risks for hepatocellular carcinoma (HCC) with respect to hepatitis B virus (HBV) genotypes, specific viral mutations (MT), serum HBV DNA levels, and cirrhosis. Methods: HBV genotypes, 1653/1753/core promoter (CP)/precore MT and HBV DNA levels were determined in 248 HBV patients with HCC and 248 HBV controls. Results: Genotype C, CP-MT, T1653, HBV DNA levels ≥4 log 10 copies/ml and cirrhosis had a higher risk for HCC compared to patients with genotype B (p = 0.001, OR 1.9), CP wild-type (WT) (p<0.001, OR 4.1), C1653 (p = 0.028, OR 2.4), HBV DNA <4 log 10 copies/ml (p = 0.003, OR 2.1) and without cirrhosis (p<0.001, OR 4.0) respectively. Multivariate analysis showed that CP-MT, T1653, HBV DNA ≥4 log 10 copies/ml and cirrhosis were independent factors for HCC (all p<0.05). A receiver operating characteristics curve showed no cut-off HBV DNA level associated with minimal chance of HCC. Patients with CP-MT and cirrhosis had a 22.2-fold increased risk of HCC compared to patients with CP-WT and without cirrhosis. Patients with CP-MT and HBV DNA levels ≥4 log 10 copies/ml had a 7.2-fold increased risk of HCC compared to patients with CP-WT and HBV DNA levels <4 log 10 copies/ml. Patients with CP-MT and T1653 had a 9.9-fold increased risk of HCC compared to patients with wild-type for both regions. Conclusions: CP-MT, T1653, HBV DNA levels ≥4 log 10 copies/ml and cirrhosis are independent factors for development of HCC. The risks increased substantially in patients having these factors in combination.
 
dc.description.naturepublished_or_final_version
 
dc.identifier.citationGut, 2008, v. 57 n. 1, p. 98-102 [How to Cite?]
DOI: http://dx.doi.org/10.1136/gut.2007.119859
 
dc.identifier.doihttp://dx.doi.org/10.1136/gut.2007.119859
 
dc.identifier.epage102
 
dc.identifier.hkuros130659
 
dc.identifier.isiWOS:000251778400021
 
dc.identifier.issn0017-5749
2013 Impact Factor: 13.319
 
dc.identifier.issue1
 
dc.identifier.openurl
 
dc.identifier.pmid17483190
 
dc.identifier.scopuseid_2-s2.0-38349138512
 
dc.identifier.spage98
 
dc.identifier.urihttp://hdl.handle.net/10722/57531
 
dc.identifier.volume57
 
dc.languageeng
 
dc.publisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofGut
 
dc.relation.referencesReferences in Scopus
 
dc.rightsGut. Copyright © B M J Publishing Group.
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.subject.meshCarcinoma, Hepatocellular - virology
 
dc.subject.meshEnhancer Elements (Genetics) - genetics
 
dc.subject.meshHepatitis B virus - genetics
 
dc.subject.meshLiver Neoplasms - virology
 
dc.subject.meshPromoter Regions (Genetics) - genetics
 
dc.titleRisk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Yuen, MF</contributor.author>
<contributor.author>Tanaka, Y</contributor.author>
<contributor.author>Shinkai, N</contributor.author>
<contributor.author>Poon, RT</contributor.author>
<contributor.author>But, DYK</contributor.author>
<contributor.author>Fong, DYT</contributor.author>
<contributor.author>Fung, J</contributor.author>
<contributor.author>Wong, DKH</contributor.author>
<contributor.author>Yuen, JCH</contributor.author>
<contributor.author>Mizokami, M</contributor.author>
<contributor.author>Lai, CL</contributor.author>
<date.accessioned>2010-04-12T01:39:15Z</date.accessioned>
<date.available>2010-04-12T01:39:15Z</date.available>
<date.issued>2008</date.issued>
<identifier.citation>Gut, 2008, v. 57 n. 1, p. 98-102</identifier.citation>
<identifier.issn>0017-5749</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/57531</identifier.uri>
<description.abstract>Background/aim: To examine the risks for hepatocellular carcinoma (HCC) with respect to hepatitis B virus (HBV) genotypes, specific viral mutations (MT), serum HBV DNA levels, and cirrhosis. Methods: HBV genotypes, 1653/1753/core promoter (CP)/precore MT and HBV DNA levels were determined in 248 HBV patients with HCC and 248 HBV controls. Results: Genotype C, CP-MT, T1653, HBV DNA levels &#8805;4 log 10 copies/ml and cirrhosis had a higher risk for HCC compared to patients with genotype B (p = 0.001, OR 1.9), CP wild-type (WT) (p&lt;0.001, OR 4.1), C1653 (p = 0.028, OR 2.4), HBV DNA &lt;4 log 10 copies/ml (p = 0.003, OR 2.1) and without cirrhosis (p&lt;0.001, OR 4.0) respectively. Multivariate analysis showed that CP-MT, T1653, HBV DNA &#8805;4 log 10 copies/ml and cirrhosis were independent factors for HCC (all p&lt;0.05). A receiver operating characteristics curve showed no cut-off HBV DNA level associated with minimal chance of HCC. Patients with CP-MT and cirrhosis had a 22.2-fold increased risk of HCC compared to patients with CP-WT and without cirrhosis. Patients with CP-MT and HBV DNA levels &#8805;4 log 10 copies/ml had a 7.2-fold increased risk of HCC compared to patients with CP-WT and HBV DNA levels &lt;4 log 10 copies/ml. Patients with CP-MT and T1653 had a 9.9-fold increased risk of HCC compared to patients with wild-type for both regions. Conclusions: CP-MT, T1653, HBV DNA levels &#8805;4 log 10 copies/ml and cirrhosis are independent factors for development of HCC. The risks increased substantially in patients having these factors in combination.</description.abstract>
<language>eng</language>
<publisher>BMJ Publishing Group. The Journal&apos;s web site is located at http://gut.bmjjournals.com/</publisher>
<relation.ispartof>Gut</relation.ispartof>
<rights>Gut. Copyright &#169; B M J Publishing Group.</rights>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<subject.mesh>Carcinoma, Hepatocellular - virology</subject.mesh>
<subject.mesh>Enhancer Elements (Genetics) - genetics</subject.mesh>
<subject.mesh>Hepatitis B virus - genetics</subject.mesh>
<subject.mesh>Liver Neoplasms - virology</subject.mesh>
<subject.mesh>Promoter Regions (Genetics) - genetics</subject.mesh>
<title>Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0017-5749&amp;volume=57&amp;issue=1&amp;spage=98&amp;epage=102&amp;date=2008&amp;atitle=Risk+for+hepatocellular+carcinoma+with+respect+to+hepatitis+B+virus+genotypes+B/C,+specific+mutations+of+enhancer+II/core+promoter/precore+regions+and+HBV+DNA+levels</identifier.openurl>
<description.nature>published_or_final_version</description.nature>
<identifier.doi>10.1136/gut.2007.119859</identifier.doi>
<identifier.pmid>17483190</identifier.pmid>
<identifier.scopus>eid_2-s2.0-38349138512</identifier.scopus>
<identifier.hkuros>130659</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-38349138512&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>57</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>98</identifier.spage>
<identifier.epage>102</identifier.epage>
<identifier.isi>WOS:000251778400021</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
<bitstream.url>http://hub.hku.hk/bitstream/10722/57531/1/134087.pdf</bitstream.url>
</item>
Author Affiliations
  1. Nagoya City University
  2. The University of Hong Kong